Why Replimune Stock Jumped After a 10-3 FDA Panel Backing-and Why the Real Test Comes in Days

The rally is a bet on FDA follow-through, not just panel theater

The core event was straightforward. On July 30, 2026, the FDA advisory panel voted 10-3 that the IGNYTE data for RP1 plus nivolumab in anti-PD-1-resistant advanced melanoma were evaluable and clinically meaningful, and the agency's target action date is August 2, 2026. That is why the stock moved. Reuters reported shares more than doubled premarket after the vote.

That reaction makes sense because advisory panels often influence FDA decision-making, and panels generally follow the recommendations under review. A 10-to-3 vote is a strong signal, even if it is still only advice.

Still, investors should keep the setup simple. The FDA has already turned RP1 back twice, and if it does so again, Replimune could face a wait into late 2027 for confirmatory trial results before a new submission. The immediate question is no longer whether the meeting went well. It is whether the FDA is likely to act on that outcome within days.

RP1 has a credible mechanism, but the approval debate is still about evidence strength

What RP1 is and why the combination makes sense

RP1 is an engineered HSV-1 oncolytic immunotherapy. In plain English, Replimune designed it to attack tumor cells directly, release tumor antigens, alter the tumor microenvironment, and potentially help the immune system recognize cancer more effectively. That is why the company has pushed RP1 in combination with nivolumab, especially in patients who have already progressed on anti-PD-1 therapy.

Why the IGNYTE data caught the panel's attention

The panel was reviewing data from a very hard-to-treat patient population: people whose melanoma progressed after prior PD-1 treatment. In that context, the efficacy signals were compelling enough for the committee to call them evaluable and clinically meaningful.

That does not end the debate. The same meeting materials also highlighted trial-design limitations, and one panelist said she still wanted phase 3 data to answer the question more definitively. In other words, the data can look clinically useful and still fall short of what the FDA wants for approval.

Where the bear case still stands

The bear case is not that RP1 lacks any signal. It is that single-arm evidence can be hard to interpret. Even supporters of the data have to acknowledge that a control arm would make causal claims much stronger. For now, the debate is less about whether patients benefited and more about whether the FDA is willing to rely on this evidence base in this setting.

What next decides whether REPL stays higher: the FDA letter and the August 2 goal date

The next catalyst is the FDA's August 2, 2026 goal date. After the panel's 10-3 favorable vote on RP1 plus nivolumab in anti–PD-1–resistant advanced melanoma, investors are no longer betting on a good meeting. They are betting the agency acts on it.

Why bulls think the upside may still be underappreciated

Bulls are not just looking for a deferral or another review cycle. They are looking for approval. Advisory committees generally follow the recommendations, so the key question is whether the FDA treats the panel's view as the basis for a decision.

There is also a broader commercial angle. Replimune says RP1 candidates are expected to be synergistic with many established and experimental cancer treatment modalities. If RP1 wins approval even in a narrow setting, investors may start valuing it less as a one-indication story and more as a platform with wider combo potential.

What bears will watch in the FDA response

Bears do not need to argue that RP1 lacks activity. They need to argue that the application still leaves key questions unanswered. If the FDA letter still leans on single-arm evidence without resolving the causation debate, skeptics will say the bar was not truly cleared.

The signals that matter most are simple:

• Upside: the FDA approves RP1 by the August 2 target in a narrow melanoma setting.
• Downside: the FDA rejects RP1 again, pushing Replimune toward a wait into late 2027 for confirmatory trial results before a new submission.